Drug Trial Radar · NCT06034977
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
Jul 23, 2026
Study completion Jul 23, 2026
Sponsor
- Lead sponsor
- Chang Gung Memorial HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the clinical outcomes of Lenvatinib treatment alone or Lenvatinib + ADI-PEG20 combination treatment in advanced HCC patients with BCLC stage C.
Conditions
- Hepatocellular Carcinoma
Interventions
ADI-PEG20Drug
Lenvatinib + ADI-PEG20 combination treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: 2 years after the last enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chang Gung Memorial Hospital, Linkou branch
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.